韩国创新医疗技术支付政策及启示  

Payment policy of innovative health technology in South Korea and enlightenment

作　　者：程文迪 王海银[1] 金春林[1] CHENG Wendi;WANG Haiyin;JIN Chunlin(Shanghai Health Development Research Center(Shanghai Medical Information Center),Shanghai 200040,China)

机构地区：[1]上海市卫生和健康发展研究中心(上海市医学科学技术情报研究所),上海200040

出　　处：《中国卫生资源》2020年第1期55-58,共4页Chinese Health Resources

摘　　要：综述韩国国民健康保险体系中创新医疗技术的支付经验,特别是创新药品以及按疾病诊断相关分组支付方式下的创新医疗技术支付政策。在此基础上提出完善我国创新医疗技术收付费政策的建议:引入卫生技术评估的理念和方法;建立多部门合作的卫生技术评估决策转换机制;针对没有成本效果的药物或循证证据不够充分的药物(如罕见病用药和抗癌药等),引入风险共担协议,保证患者的药品可及性。Experience on payment of innovative health technology in the national health insurance system of South Korea was summarized,especially innovative drugs and innovative health technology under diagnosis related groups(DRGs)payment method.On this basis,some suggestions on perfecting the policy of pricing and payment for innovative health technology in China were put forward:introducing health technology assessment concept and methods,establishing multisectoral cooperation on decision-making conversion in health technology assessment,and adding drugs in use that were not cost-effective or not sufficiently evidence-based(orphan drugs and anti-cancer drugs for instance)to risk-sharing agreements to ensure patients’accessibility to drugs.

关 键 词：创新药品 创新医疗技术 支付政策 国民健康保险公团 健康保险审查评价院 疾病诊断相关分组 医疗保险支付方式 卫生技术评估 风险共担 韩国 

分 类 号：R19-0[医药卫生—卫生事业管理] R199[医药卫生—公共卫生与预防医学]